- Published on
Medicine – Non-Hodgkin Lymphomas (NHLs)
Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of malignant lymphoid neoplasms characterised by clonal proliferation of B lymphocytes, T lymphocytes or natural killer (NK) cells.
They commonly arise in lymph nodes but may also originate in extranodal tissues, including the gastrointestinal tract, skin, bone marrow and central nervous system.
Approximately 85–90% of NHLs are of B-cell origin, although the distribution varies geographically and by lymphoma subtype.
Non-Hodgkin lymphoma is not a single disease. It comprises many distinct lymphoid malignancies with different growth rates, clinical presentations, molecular abnormalities, prognoses and treatment strategies.
1. Classification of Non-Hodgkin Lymphomas
NHLs are classified according to cellular origin, histological subtype and clinical behaviour.
Traditional classifications describe low-grade, intermediate-grade and high-grade lymphomas. Modern classification systems identify specific pathological and molecular entities, often grouped clinically as indolent or aggressive lymphomas.
| Classification | Clinical Behaviour | Examples |
|---|---|---|
| Low-grade / Indolent | Slowly progressive | Follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma |
| Intermediate-grade / Aggressive | Rapidly progressive | Diffuse large B-cell lymphoma (DLBCL) |
| High-grade / Highly Aggressive | Very rapid progression | Burkitt lymphoma, certain high-grade B-cell lymphomas |
2. Pathophysiology
NHL develops through acquired genetic and molecular abnormalities that promote uncontrolled lymphocyte proliferation and survival.
These abnormalities may interfere with normal cell-cycle regulation, apoptosis, lymphocyte differentiation and immune signalling.
Pathophysiology Flowchart
Important Genetic Abnormalities
| Genetic Abnormality | Associated Lymphoma |
|---|---|
| t(14;18), BCL2 | Follicular lymphoma |
| MYC rearrangement | Burkitt lymphoma |
| BCL6 abnormalities | Some diffuse large B-cell lymphomas |
| t(11;14), CCND1 / cyclin D1 | Mantle cell lymphoma |
3. Low-Grade (Indolent) Non-Hodgkin Lymphomas
Low-grade lymphomas generally follow a slowly progressive course and may remain asymptomatic for prolonged periods.
A. Clinical Presentation
Slowly progressive, painless peripheral lymphadenopathy is a common presenting feature.
- Slowly enlarging lymph nodes.
- Usually painless and rubbery lymphadenopathy.
- Generalised lymphadenopathy may occur.
- Symptoms may be absent for months or years.
B. Extranodal Involvement
Indolent lymphoma may involve the gastrointestinal tract, skin, bone marrow and other tissues.
C. B Symptoms
B symptoms include:
- Unexplained fever above 38°C.
- Drenching night sweats.
- Unintentional weight loss exceeding 10% of body weight over six months.
B symptoms may be absent, especially in early or asymptomatic indolent disease.
D. Bone Marrow Involvement
Bone marrow infiltration is common in several indolent lymphoma subtypes.
It may cause:
- Anaemia.
- Neutropenia.
- Thrombocytopenia.
- Pancytopenia in advanced disease.
E. Splenomegaly
Splenomegaly may occur, particularly in advanced disease or specific lymphoma subtypes.
The traditional estimate of approximately 40% is not applicable to all low-grade NHLs because the frequency varies substantially by subtype and stage.
4. Intermediate- and High-Grade (Aggressive) Non-Hodgkin Lymphomas
Aggressive NHLs typically progress more rapidly than indolent lymphomas and may produce substantial tumour masses over a period of weeks.
A. Lymphadenopathy
The most common presentation is rapidly enlarging lymphadenopathy.
- Rapidly growing lymph nodes.
- Bulky lymphadenopathy.
- Cervical, axillary, inguinal, mediastinal or abdominal lymph node involvement.
- Compression of adjacent structures.
B. Extranodal Involvement
Extranodal involvement is common in some aggressive lymphoma subtypes.
Potential sites include:
- Gastrointestinal tract.
- Skin.
- Bone marrow.
- Paranasal sinuses.
- Genitourinary tract.
- Thyroid gland.
- Bone.
- Central nervous system.
C. Organ Enlargement
- Splenomegaly.
- Hepatomegaly.
- Large abdominal masses.
- Mediastinal masses.
D. B Symptoms
B symptoms occur more frequently in many aggressive lymphomas than in indolent lymphomas.
Fever, drenching night sweats and significant unintentional weight loss may accompany rapid tumour growth.
E. Other Clinical Manifestations
- Fatigue and anorexia.
- Abdominal pain or bowel obstruction.
- Superior vena cava obstruction.
- Neurological deficits due to CNS or spinal involvement.
- Elevated lactate dehydrogenase (LDH).
- Tumour lysis syndrome, particularly in rapidly proliferating disease.
5. Comparison: Indolent vs Aggressive NHL
| Feature | Indolent NHL | Aggressive NHL |
|---|---|---|
| Progression | Slow | Rapid |
| Lymphadenopathy | Slowly enlarging, painless | Rapidly enlarging, potentially bulky |
| B symptoms | Often absent initially | More frequently present |
| Bone marrow involvement | Common in several subtypes | Variable |
| Extranodal involvement | May occur | Common in some subtypes |
| Treatment urgency | Observation possible in selected cases | Usually prompt treatment |
| Treatment outcome | Often responsive but prone to relapse | Some subtypes potentially curable |
6. Diagnosis
A. Lymph Node Biopsy
Excisional lymph node biopsy is preferred when feasible because it preserves tissue architecture for histopathological assessment.
An adequate core needle biopsy may be used when excision is impractical.
Fine-needle aspiration alone is generally insufficient for initial definitive lymphoma classification.
B. Histopathology and Immunophenotyping
Biopsy specimens may undergo:
- Histopathological examination.
- Immunohistochemistry.
- Flow cytometry when appropriate.
- Cytogenetic and molecular investigations.
Important Immunophenotypic Markers
| Marker | Significance |
|---|---|
| CD20 | B-cell marker and therapeutic target |
| CD3 | T-cell marker |
| CD10 | Germinal-centre marker in selected B-cell lymphomas |
| CD5 | Expressed in certain B-cell and T-cell lymphomas |
| BCL2 | Anti-apoptotic protein |
| BCL6 | Germinal-centre-associated marker |
| Ki-67 | Proliferation index |
C. Blood Investigations
- Full blood count to identify anaemia and other cytopenias.
- LDH as a marker of cell turnover and prognostic risk.
- Renal function and electrolytes.
- Liver function tests.
- Uric acid.
- Hepatitis B, hepatitis C and HIV testing when clinically appropriate, particularly before immunochemotherapy.
D. Imaging
CT and/or FDG-PET/CT are used to assess disease distribution and stage.
FDG-PET/CT is particularly useful in many FDG-avid lymphomas, including DLBCL.
E. Bone Marrow Examination
Bone marrow biopsy may be indicated in selected patients depending on lymphoma subtype, staging findings and whether the result would change management.
It is not universally required for every patient with NHL.
F. Cytogenetics and Molecular Testing
Testing may identify MYC, BCL2, BCL6 or other abnormalities relevant to lymphoma classification, prognosis and treatment planning.
Diagnostic Flowchart
7. Ann Arbor / Lugano Staging
The Lugano classification is commonly used for staging NHL and incorporates the traditional Ann Arbor anatomical stages.
| Stage | Description |
|---|---|
| I | Single lymph node region or a single localized extranodal site |
| II | Two or more lymph node regions on the same side of the diaphragm |
| III | Lymph node involvement on both sides of the diaphragm |
| IV | Diffuse or disseminated extranodal involvement, such as liver or bone marrow |
Staging must be interpreted alongside lymphoma subtype, tumour burden, symptoms and prognostic factors.
8. Management of Non-Hodgkin Lymphomas
Treatment depends on lymphoma subtype, stage, symptoms, tumour burden, patient fitness and molecular characteristics.
A. Indolent NHL
Selected asymptomatic patients with low tumour burden may undergo active surveillance (watch and wait).
When treatment is indicated, options may include:
- Rituximab-based therapy for appropriate CD20-positive B-cell lymphomas.
- Immunochemotherapy.
- Local radiotherapy for selected localized disease.
- Targeted treatments in appropriate subtypes.
- Other systemic treatments for relapsed disease.
B. Aggressive B-Cell NHL
Aggressive lymphomas generally require prompt systemic treatment.
For many patients with diffuse large B-cell lymphoma, treatment may include:
- R-CHOP: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone/prednisone.
- Polatuzumab-R-CHP: An option for selected patients with DLBCL, depending on eligibility and local guidelines.
Other aggressive lymphoma subtypes require different treatment protocols.
C. Radiotherapy
Radiotherapy may be used for selected localized lymphomas, consolidation in certain settings or symptom relief.
D. Relapsed or Refractory NHL
Depending on subtype and eligibility, options may include:
- Salvage chemotherapy.
- Autologous stem cell transplantation.
- CAR-T-cell therapy.
- Bispecific antibodies.
- Targeted agents and other immunotherapies.
E. Supportive Management
- Infection prevention and treatment.
- Management of anaemia and other cytopenias.
- Nutritional support.
- Monitoring for treatment-related toxicity.
- Tumour lysis syndrome prophylaxis in high-risk patients.
Treatment Flowchart
9. Important Complications
- Bone marrow failure and cytopenias.
- Severe infections.
- Organ compression by bulky lymphadenopathy.
- Spinal cord compression.
- CNS involvement in selected subtypes.
- Tumour lysis syndrome.
- Transformation of indolent lymphoma into aggressive lymphoma.
- Treatment-related toxicity.
10. High-Yield Examination Summary
| Feature | Key Point |
|---|---|
| Definition | Clonal malignancy of B, T or NK lymphocytes |
| Most common cellular origin | B cells |
| Common presentation | Painless lymphadenopathy |
| Indolent NHL | Slowly progressive lymphadenopathy |
| Aggressive NHL | Rapidly enlarging, bulky lymphadenopathy |
| B symptoms | Fever, drenching night sweats, weight loss |
| Extranodal sites | GI tract, skin, bone marrow, CNS and others |
| Diagnosis | Tissue biopsy with immunophenotyping |
| Staging | CT/PET-CT and Lugano classification |
| Common aggressive subtype | Diffuse large B-cell lymphoma |
| Treatment | Subtype-specific systemic therapy ± radiotherapy |
11. Key Examination Pearls
- NHL is a heterogeneous group of lymphoid malignancies rather than a single disease.
- Most NHLs arise from B lymphocytes.
- Painless lymphadenopathy is a classic presentation.
- Indolent lymphomas usually grow slowly and may initially require observation only.
- Aggressive lymphomas progress rapidly but may be curable with treatment.
- B symptoms are unexplained fever, drenching night sweats and significant weight loss.
- Extranodal involvement is an important feature of NHL.
- Excisional biopsy is preferred when feasible for definitive diagnosis.
- Immunophenotyping and molecular investigations determine lymphoma subtype.
- Bone marrow biopsy is selectively performed rather than mandatory for every patient.
- Treatment is guided by lymphoma subtype, stage, patient fitness and prognostic features.
Persistent painless lymphadenopathy, particularly when accompanied by B symptoms, splenomegaly or an extranodal mass, should raise suspicion of non-Hodgkin lymphoma. Definitive diagnosis requires adequate tissue biopsy and pathological classification before selecting treatment.
Rapidly enlarging masses, airway compromise, neurological deficits, suspected spinal cord compression or tumour lysis syndrome require urgent medical assessment. NHL management should be individualised by a specialist haematology team.
Kembara Xtra – Medicine Revision Notes